Brain Tumors: Molecular and Cell Biology for Target Therapy

Dear Colleagues,

Epidemiological data indicate that cancer incidence is rapidly growing. Inheritance, gender, geography, and exposure to electromagnetic radiations are among the etiological factors of brain tumors. Most malignant primary tumors of the adult brain originate from glial cells or glial cell precursors and are so-called gliomas. Malignant gliomas are highly invasive, neurologically destructive, and characterized by high tumor heterogeneity, uncontrolled proliferation, and resistance to therapies. Among these tumors, glioblastoma is the deadliest.

In 2016, the World Health Organization (WHO) provided new guidelines for cerebral neoplasm, introducing molecular markers in addition to the classic histopathological criteria.

This new approach integrates genotypic and phenotypic parameters, increasing the accuracy of the diagnostic procedure in order to facilitate the implementation of targeted treatments. Despite these new criteria, brain tumors still lack effective treatments. Currently available therapeutic options neglect the individuality of each patient’s disease and only temporarily influence tumor progression with a poor effect on overall survival, highlighting the great importance of the introduction of target treatments in neuro-oncology.

This Special Issue will highlight the importance of exploring brain tumors at cellular and molecular levels, to outline novel strategic approaches for brain tumor target therapy. With this issue, we aim to advance brain tumor cure, dissecting all aspects ranging from basic biology to translational medicine.

Dr. Stefania Navone
Dr. Giovanni Marfia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.